FI3452053T3 - Menetelmä alempien virtsateiden uroteelisyövän hoitamiseksi - Google Patents
Menetelmä alempien virtsateiden uroteelisyövän hoitamiseksi Download PDFInfo
- Publication number
- FI3452053T3 FI3452053T3 FIEP17793523.6T FI17793523T FI3452053T3 FI 3452053 T3 FI3452053 T3 FI 3452053T3 FI 17793523 T FI17793523 T FI 17793523T FI 3452053 T3 FI3452053 T3 FI 3452053T3
- Authority
- FI
- Finland
- Prior art keywords
- antimetabolite
- use according
- gemcitabine
- administered
- bladder
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 7
- 206010044412 transitional cell carcinoma Diseases 0.000 title claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 19
- 229940100197 antimetabolite Drugs 0.000 claims 19
- 239000002256 antimetabolite Substances 0.000 claims 19
- 229960005277 gemcitabine Drugs 0.000 claims 11
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 11
- 206010005003 Bladder cancer Diseases 0.000 claims 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000002519 immonomodulatory effect Effects 0.000 claims 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- AJWTXSLKVJNYAB-UHFFFAOYSA-N 4-n-(4,5-dihydro-1h-imidazol-2-yl)-1-n-[4-(4,5-dihydro-1h-imidazol-2-ylamino)phenyl]benzene-1,4-diamine Chemical compound N1CCN=C1NC(C=C1)=CC=C1NC(C=C1)=CC=C1NC1=NCCN1 AJWTXSLKVJNYAB-UHFFFAOYSA-N 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 2
- 102000002698 KIR Receptors Human genes 0.000 claims 2
- 108010043610 KIR Receptors Proteins 0.000 claims 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 230000002250 progressing effect Effects 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100038078 CD276 antigen Human genes 0.000 claims 1
- 101710185679 CD276 antigen Proteins 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 102100031351 Galectin-9 Human genes 0.000 claims 1
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000836877 Homo sapiens Sialic acid-binding Ig-like lectin 11 Proteins 0.000 claims 1
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 claims 1
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- -1 ICOS Proteins 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 101150030213 Lag3 gene Proteins 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 102100027125 Sialic acid-binding Ig-like lectin 11 Human genes 0.000 claims 1
- 102100029957 Sialic acid-binding Ig-like lectin 5 Human genes 0.000 claims 1
- 101710110535 Sialic acid-binding Ig-like lectin 5 Proteins 0.000 claims 1
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 claims 1
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 claims 1
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0216—Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Epoxy Compounds (AREA)
- Saccharide Compounds (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662333151P | 2016-05-06 | 2016-05-06 | |
| US201762443614P | 2017-01-06 | 2017-01-06 | |
| PCT/US2017/031445 WO2017193098A1 (en) | 2016-05-06 | 2017-05-05 | Method of treating lower tract urothelial cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3452053T3 true FI3452053T3 (fi) | 2023-04-12 |
Family
ID=60203435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17793523.6T FI3452053T3 (fi) | 2016-05-06 | 2017-05-05 | Menetelmä alempien virtsateiden uroteelisyövän hoitamiseksi |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20190388338A1 (enExample) |
| EP (2) | EP3452053B1 (enExample) |
| JP (3) | JP7712055B2 (enExample) |
| KR (2) | KR20220123317A (enExample) |
| CN (2) | CN109475571A (enExample) |
| AU (1) | AU2017261371B2 (enExample) |
| CA (1) | CA3023274A1 (enExample) |
| ES (1) | ES2940227T3 (enExample) |
| FI (1) | FI3452053T3 (enExample) |
| HR (1) | HRP20221544T1 (enExample) |
| HU (1) | HUE060965T2 (enExample) |
| IL (2) | IL295592A (enExample) |
| LT (1) | LT3452053T (enExample) |
| MX (2) | MX389296B (enExample) |
| NZ (3) | NZ787786A (enExample) |
| PL (1) | PL3452053T3 (enExample) |
| PT (1) | PT3452053T (enExample) |
| RS (1) | RS64032B1 (enExample) |
| RU (2) | RU2022100624A (enExample) |
| SG (2) | SG10201913416PA (enExample) |
| SI (1) | SI3452053T1 (enExample) |
| SM (1) | SMT202300047T1 (enExample) |
| WO (1) | WO2017193098A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3370768T1 (sl) | 2015-11-03 | 2022-04-29 | Janssen Biotech, Inc. | Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe |
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| WO2019023388A1 (en) * | 2017-07-25 | 2019-01-31 | Taris Biomedical Llc | METHODS OF TREATING TUMOR METASTASIS |
| PE20210041A1 (es) * | 2017-11-08 | 2021-01-08 | Taris Biomedical Llc | Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY30915A1 (es) * | 2007-02-16 | 2008-09-02 | Smithkline Beecham Corp | Método de tratamiento de canceres |
| US8343516B2 (en) | 2009-06-26 | 2013-01-01 | Taris Biomedical, Inc. | Solid drug tablets for implantable drug delivery devices |
| US8679094B2 (en) | 2009-12-17 | 2014-03-25 | Taris Biomedical, Inc. | Implantable device with intravesical tolerability and methods of treatment |
| WO2011153009A1 (en) * | 2010-06-02 | 2011-12-08 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| PT2600800T (pt) | 2010-08-05 | 2020-11-05 | Taris Biomedical Llc | Dispositivo de administração de drogas por stent ureteral, kit e método |
| WO2012106714A1 (en) | 2011-02-04 | 2012-08-09 | Taris Biomedical, Inc. | Implantable device for controlled release of low solubility drug |
| US20150216937A1 (en) * | 2012-03-29 | 2015-08-06 | Altor Bioscience Corporation | Methods for treating neoplasia |
| KR102383496B1 (ko) | 2012-08-31 | 2022-04-08 | 타리스 바이오메디컬 엘엘씨 | 젬시타빈을 포함하는 전립선 질환의 치료를 위한 약물 전달 시스템과 방법 |
| RU2657591C2 (ru) * | 2012-08-31 | 2018-06-14 | ТАРИС Биомедикал ЛЛК | Способ лечения рака мочевого пузыря оксалиплатином, соответствующее устройство его доставки, способ и устройство его введения |
| JP2016508842A (ja) | 2013-03-05 | 2016-03-24 | タリス バイオメディカル エルエルシー | 装置の開口部を通じて制御された薬物放出のための薬物送達装置及び方法 |
| EP2968120A1 (en) | 2013-03-15 | 2016-01-20 | TARIS Biomedical LLC | Drug delivery devices and methods for drug delivery |
| SG11201507294WA (en) | 2013-03-15 | 2015-10-29 | Taris Biomedical Llc | Drug delivery devices with drug-permeable component and methods |
| WO2015026813A1 (en) | 2013-08-19 | 2015-02-26 | Taris Biomedical Llc | Multi-unit drug delivery devices and methods |
| HRP20251264T1 (hr) * | 2014-03-06 | 2025-12-05 | Taris Biomedical Llc | Sustavi za primjenu lijeka i metode za liječenje karcinoma mokraćnog mjehura gemcitabinom |
| KR102391761B1 (ko) | 2014-06-26 | 2022-04-27 | 타리스 바이오메디컬 엘엘씨 | 탄성 폴리머-약물 매트릭스 시스템을 포함하는 방광내 약물 전달 장치 및 방법 |
| WO2016172704A1 (en) | 2015-04-23 | 2016-10-27 | Taris Biomedical Llc | Drug delivery devices with drug-permeable component and methods |
-
2017
- 2017-05-05 ES ES17793523T patent/ES2940227T3/es active Active
- 2017-05-05 SG SG10201913416PA patent/SG10201913416PA/en unknown
- 2017-05-05 IL IL295592A patent/IL295592A/en unknown
- 2017-05-05 RU RU2022100624A patent/RU2022100624A/ru unknown
- 2017-05-05 KR KR1020227028547A patent/KR20220123317A/ko not_active Ceased
- 2017-05-05 WO PCT/US2017/031445 patent/WO2017193098A1/en not_active Ceased
- 2017-05-05 SI SI201731301T patent/SI3452053T1/sl unknown
- 2017-05-05 US US16/099,179 patent/US20190388338A1/en active Pending
- 2017-05-05 AU AU2017261371A patent/AU2017261371B2/en active Active
- 2017-05-05 MX MX2018013432A patent/MX389296B/es unknown
- 2017-05-05 SM SM20230047T patent/SMT202300047T1/it unknown
- 2017-05-05 CN CN201780040391.1A patent/CN109475571A/zh active Pending
- 2017-05-05 NZ NZ787786A patent/NZ787786A/en unknown
- 2017-05-05 HU HUE17793523A patent/HUE060965T2/hu unknown
- 2017-05-05 PL PL17793523.6T patent/PL3452053T3/pl unknown
- 2017-05-05 NZ NZ748252A patent/NZ748252A/en unknown
- 2017-05-05 SG SG11201809838VA patent/SG11201809838VA/en unknown
- 2017-05-05 CA CA3023274A patent/CA3023274A1/en active Pending
- 2017-05-05 LT LTEPPCT/US2017/031445T patent/LT3452053T/lt unknown
- 2017-05-05 CN CN202410626384.1A patent/CN118453872A/zh active Pending
- 2017-05-05 RS RS20230163A patent/RS64032B1/sr unknown
- 2017-05-05 HR HRP20221544TT patent/HRP20221544T1/hr unknown
- 2017-05-05 KR KR1020187035297A patent/KR102435709B1/ko active Active
- 2017-05-05 FI FIEP17793523.6T patent/FI3452053T3/fi active
- 2017-05-05 RU RU2018142908A patent/RU2764747C2/ru active
- 2017-05-05 EP EP17793523.6A patent/EP3452053B1/en active Active
- 2017-05-05 PT PT177935236T patent/PT3452053T/pt unknown
- 2017-05-05 NZ NZ787824A patent/NZ787824A/en unknown
- 2017-05-05 IL IL262746A patent/IL262746B/en unknown
- 2017-05-05 JP JP2018558199A patent/JP7712055B2/ja active Active
- 2017-05-05 EP EP22212024.8A patent/EP4209221A1/en active Pending
-
2018
- 2018-11-01 MX MX2021013461A patent/MX2021013461A/es unknown
-
2021
- 2021-10-21 JP JP2021172052A patent/JP2022009327A/ja not_active Withdrawn
-
2023
- 2023-12-07 JP JP2023206570A patent/JP2024028881A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3452053T3 (fi) | Menetelmä alempien virtsateiden uroteelisyövän hoitamiseksi | |
| JP2019522657A5 (enExample) | ||
| RU2019101804A (ru) | Комбинированная терапия | |
| RU2017112379A (ru) | Сочетанные способы лечения с использованием ингибиторов alk | |
| Smyth et al. | Combination cancer immunotherapies tailored to the tumour microenvironment | |
| JP2016525117A5 (enExample) | ||
| ES2754557T3 (es) | Combinación de un anticuerpo CD30XCD16A con un anticuerpo antagonista anti-PD-1 para terapia | |
| FI3778641T3 (fi) | Bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat CD3:a ja CD20:tä, ja niiden käyttöjä | |
| US20220144943A1 (en) | Anti-cd47 antibodies and uses thereof | |
| RU2018100944A (ru) | Противораковое средство | |
| Kumar et al. | A phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM) | |
| CN111163798A (zh) | 用于抗lag-3抗体的给药方案及其用途 | |
| RU2016131170A (ru) | Способы и композиции для лечения персистирующих инфекций | |
| JP2018518939A5 (enExample) | ||
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| JP2017532372A5 (enExample) | ||
| HRP20240357T1 (hr) | Stanica | |
| HRP20180945T1 (hr) | Konjugati protutijelo-pirolobenzodiazepin | |
| FI3630143T3 (fi) | Onkolyyttinen virus ja menetelmä | |
| JP2019514970A5 (enExample) | ||
| RU2018102575A (ru) | Антитела против человеческого csf-1r, предназначенные для применения для индукции лимфоцитоза при лимфомах или лейкозах | |
| Gagelmann et al. | B cell maturation antigen-specific CAR T Cells for relapsed or refractory multiple myeloma: a meta-analysis | |
| CN119923256A (zh) | 包含大麻素的连续递送系统及其医药用途 | |
| Costa et al. | Phase 2 trial of intracycle sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia | |
| Gladstone et al. | Results of a phase 2 study of MEDI-551 and bendamustine vs rituximab and bendamustine in relapsed or refractory chronic lymphocytic leukemia |